SAT-035 Small Molecule Allosteric Agonist of Relaxin Receptor Ml290 Demonstrates Antifibrotic Properties in Liver Fibrosis

Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological therapeutic options. The beneficial effects of relaxin peptide treatment have been demonstrated previously in clinically relevant animal models of liver disease. However...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Endocr Soc
Glavni autori: Kaftanovskaya, Elena, Ng, Hooi Hooi, Rivas, Bryan, Myhr, Courtney, Shupe, Thomas, Hu, Xin, Ferrer, Marc, Southall, Noel, Wilson, Kenneth, Marugan, Juan, Bishop, Colin, Agoulnik, Irina, Agoulnik, Alexander
Format: Artigo
Jezik:Inglês
Izdano: Endocrine Society 2019
Teme:
Non-Steroid Hormone Signaling
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552156/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-035
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items